Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2010

01.05.2010 | Colorectal Cancer

High Level of Notch1 Protein is Associated with Poor Overall Survival in Colorectal Cancer

verfasst von: Dake Chu, MD, Yunming Li, MD, Weizhong Wang, MM, Qingchuan Zhao, MD, Jipeng Li, MD, Yuanyuan Lu, MD, Mengbin Li, MD, Guanglong Dong, MD, Hongwei Zhang, MD, Huahong Xie, MD, Gang Ji, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Notch1 regulates cell proliferation, development, and apoptosis. Aberrant expression of Notch1 has been discovered in many types of tumors. We examined Notch1 expression in colorectal cancer to assess its role as a prognostic indicator.

Methods

Notch1 protein expression was examined by immunohistochemistry in 223 surgically resected specimens of colorectal cancer and adjacent tissues. The relationship between various clinicopathological features and overall patient survival rate was analyzed. The association of Notch1 expression with the colorectal cancer survival rate was assessed by Kaplan–Meier and Cox proportional-hazards regression.

Results

Significantly high Notch1 expression was found in colorectal cancer cells compared with that of normal colorectal epithelial cells. Notch1 was positively correlated with depth of invasion (P = 0.005), lymph node metastases (P = 0.03), and tumor–node–metastasis (TNM) stage (P < 0.001). Consistently, the overall survival rate was significantly lower for patients with Notch1-positive than those with Notch1-negative tumors. However, no correlation between Notch1 expression and patient age, sex or tumor location was found.

Conclusion

Notch1 might serve as a novel prognostic marker that is independent of, and additive to, the TNM staging system.
Literatur
1.
Zurück zum Zitat Wang J. Current and future situation of colorectal carcinoma screening. J Dig Surg. 2006;5:303–5 Wang J. Current and future situation of colorectal carcinoma screening. J Dig Surg. 2006;5:303–5
2.
Zurück zum Zitat Fang SG, Yang JZ, Yang F. Clinical characteristics of 610 cases with multiple primary malignant neoplasm’s in digestive tract. Shijie Huaren Xiaohua Zazhi. 1999;7:812 Fang SG, Yang JZ, Yang F. Clinical characteristics of 610 cases with multiple primary malignant neoplasm’s in digestive tract. Shijie Huaren Xiaohua Zazhi. 1999;7:812
3.
Zurück zum Zitat Wang MR, Guo CH, Li MS, Yu GP, Yin XS, Cui GP, et al. A case-control study on the dietary risk factors of upper digestive tract cancer. Zhonghua Liuxingbingxue Zazhi. 1999;20:95–7PubMed Wang MR, Guo CH, Li MS, Yu GP, Yin XS, Cui GP, et al. A case-control study on the dietary risk factors of upper digestive tract cancer. Zhonghua Liuxingbingxue Zazhi. 1999;20:95–7PubMed
4.
Zurück zum Zitat Yu BM, Zhao R. Molecular biology of colorectal carcinoma. Shijie Huaren Xiaohua Zazhi. 1999;7:173–5 Yu BM, Zhao R. Molecular biology of colorectal carcinoma. Shijie Huaren Xiaohua Zazhi. 1999;7:173–5
5.
Zurück zum Zitat Chen SY, Wu TF, Liu HY, Wang JY, Zhang SS, Zhang XD. Hospital-based ten-year data of gastroendoscopy. Shijie Huaren Xiaohua Zazhi. 1999;7:15–17 Chen SY, Wu TF, Liu HY, Wang JY, Zhang SS, Zhang XD. Hospital-based ten-year data of gastroendoscopy. Shijie Huaren Xiaohua Zazhi. 1999;7:15–17
6.
Zurück zum Zitat Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398–403.CrossRefPubMed Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398–403.CrossRefPubMed
7.
Zurück zum Zitat Miele L, Osborne B. Arbiter of differentiation and death: notch signaling meets apoptosis. J Cell Physiol. 1999;181:393–409.CrossRefPubMed Miele L, Osborne B. Arbiter of differentiation and death: notch signaling meets apoptosis. J Cell Physiol. 1999;181:393–409.CrossRefPubMed
8.
Zurück zum Zitat Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer. 1993, 72 :2979–85.CrossRefPubMed Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer. 1993, 72 :2979–85.CrossRefPubMed
9.
Zurück zum Zitat Greenwald I. LIN-12/Notch signaling: lessons from worms and flies. Genes Dev. 1998;12:1751–62.CrossRefPubMed Greenwald I. LIN-12/Notch signaling: lessons from worms and flies. Genes Dev. 1998;12:1751–62.CrossRefPubMed
10.
Zurück zum Zitat Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–6.CrossRefPubMed Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–6.CrossRefPubMed
11.
Zurück zum Zitat Bigas A, Martin DI, Milner LA. Notch1 and Notch2 inhibit myeloid differentiation in response to different cytokines. Mol Cell Biol. 1998;18:2324–33.PubMed Bigas A, Martin DI, Milner LA. Notch1 and Notch2 inhibit myeloid differentiation in response to different cytokines. Mol Cell Biol. 1998;18:2324–33.PubMed
12.
13.
Zurück zum Zitat Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999;18:5973–81.CrossRefPubMed Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999;18:5973–81.CrossRefPubMed
14.
Zurück zum Zitat Kiaris H, Politi K, Grimm LM, et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol. 2004;165:695–705.PubMed Kiaris H, Politi K, Grimm LM, et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol. 2004;165:695–705.PubMed
15.
Zurück zum Zitat Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev. 2004;14:48–54.CrossRefPubMed Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev. 2004;14:48–54.CrossRefPubMed
16.
Zurück zum Zitat Joutel A, Tournier-Lasserve E. Notch signalling pathway and human diseases. Semin Cell Dev Biol. 1998;9:619–25.CrossRefPubMed Joutel A, Tournier-Lasserve E. Notch signalling pathway and human diseases. Semin Cell Dev Biol. 1998;9:619–25.CrossRefPubMed
17.
Zurück zum Zitat Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33:416–21.CrossRefPubMed Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33:416–21.CrossRefPubMed
18.
Zurück zum Zitat Sriuranpong V, Borges MW, Ravi RK, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001;61:3200–5.PubMed Sriuranpong V, Borges MW, Ravi RK, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001;61:3200–5.PubMed
19.
Zurück zum Zitat Chu D, Wang W, Xie H, et al. Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg. 2009;13:253–60.CrossRefPubMed Chu D, Wang W, Xie H, et al. Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg. 2009;13:253–60.CrossRefPubMed
20.
Zurück zum Zitat Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65(18):8530–7.CrossRefPubMed Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65(18):8530–7.CrossRefPubMed
21.
Zurück zum Zitat Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000, 53:125–30CrossRefPubMed Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000, 53:125–30CrossRefPubMed
22.
Zurück zum Zitat Egan SE, St-Pierre B, Leow CC. Notch receptors, partners and regulators: from conserved domains to powerful functions. Curr Top Microbiol Immunol. 1998;228:273–324.PubMed Egan SE, St-Pierre B, Leow CC. Notch receptors, partners and regulators: from conserved domains to powerful functions. Curr Top Microbiol Immunol. 1998;228:273–324.PubMed
23.
Zurück zum Zitat Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia. 2004;9:145–63.CrossRefPubMed Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia. 2004;9:145–63.CrossRefPubMed
24.
Zurück zum Zitat Yeh TS, Wu CW, Hsu KW, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res. 2009;69:5039–48. Yeh TS, Wu CW, Hsu KW, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res. 2009;69:5039–48.
25.
Zurück zum Zitat Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004;103:3511–5.CrossRefPubMed Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004;103:3511–5.CrossRefPubMed
27.
Zurück zum Zitat Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104:57–64.PubMed Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104:57–64.PubMed
28.
Zurück zum Zitat Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104:1044–8.PubMed Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104:1044–8.PubMed
29.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.CrossRefPubMed Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.CrossRefPubMed
30.
Zurück zum Zitat Moertel CG, FlemingTR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–6.PubMed Moertel CG, FlemingTR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–6.PubMed
Metadaten
Titel
High Level of Notch1 Protein is Associated with Poor Overall Survival in Colorectal Cancer
verfasst von
Dake Chu, MD
Yunming Li, MD
Weizhong Wang, MM
Qingchuan Zhao, MD
Jipeng Li, MD
Yuanyuan Lu, MD
Mengbin Li, MD
Guanglong Dong, MD
Hongwei Zhang, MD
Huahong Xie, MD
Gang Ji, MD
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0893-7

Weitere Artikel der Ausgabe 5/2010

Annals of Surgical Oncology 5/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.